Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 28.86 -1.77% -0.52
DRNA closed down 1.77 percent on Thursday, April 22, 2021, on 1.54 times normal volume.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical DRNA trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength -1.77%
Multiple of Ten Bearish Other -1.77%
Wide Bands Range Expansion -1.77%
Overbought Stochastic Strength -1.77%
New 52 Week Closing High Bullish -5.25%
Expansion Breakout Bullish Swing Setup -5.25%
Pocket Pivot Bullish Swing Setup -5.25%
New 52 Week High Strength -5.25%
Upper Bollinger Band Walk Strength -5.25%
Older End-of-Day Signals for DRNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot about 20 hours ago
Up 1% about 21 hours ago
60 Minute Opening Range Breakout about 22 hours ago
2x Volume Pace about 23 hours ago
1.5x Volume Pace about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dicerna Pharmaceuticals, Inc. Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Diseases Disease Cancers Drug Delivery Enzymes Hemoglobin Liver Disease Syrup Amyloid Hemophilia Liver Diseases Myopathy Cardiomyopathy Hemophilia A Liver Rna Interference Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Kras Oncogene Delivery Technologies Drug Delivery Technologies Familial Amyloid Polyneuropathy Hyperoxaluria Polyneuropathy Ras Subfamily Treatment Of Various Cancers Primary Hyperoxaluria

Is DRNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.85
52 Week Low 16.5
Average Volume 755,659
200-Day Moving Average 23.01
50-Day Moving Average 26.90
20-Day Moving Average 26.72
10-Day Moving Average 28.22
Average True Range 1.53
ADX 19.44
+DI 26.72
-DI 16.26
Chandelier Exit (Long, 3 ATRs ) 26.26
Chandelier Exit (Short, 3 ATRs ) 26.41
Upper Bollinger Band 30.69
Lower Bollinger Band 22.76
Percent B (%b) 0.77
BandWidth 29.67
MACD Line 0.87
MACD Signal Line 0.50
MACD Histogram 0.3714
Fundamentals Value
Market Cap 2.17 Billion
Num Shares 75 Million
EPS -1.38
Price-to-Earnings (P/E) Ratio -20.97
Price-to-Sales 14.06
Price-to-Book 12.34
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.74
Resistance 3 (R3) 30.84 30.32 30.42
Resistance 2 (R2) 30.32 29.84 30.27 30.32
Resistance 1 (R1) 29.59 29.55 29.33 29.49 30.21
Pivot Point 29.07 29.07 28.94 29.02 29.07
Support 1 (S1) 28.34 28.59 28.08 28.24 27.51
Support 2 (S2) 27.82 28.30 27.77 27.40
Support 3 (S3) 27.09 27.82 27.30
Support 4 (S4) 26.99